MorrisonB.: Prazosin Hydrochloride, Drug Intell. Clin. Pharm.13: 212–215, 1979.
2.
MillerR.: Sustained Reduction of Cardiac Impedance and Preload in Congestive Heart Failure with the Antihypertensive Vasodilator Prazosin, N. Engl. J. Med.297: 303–307, 1977.
3.
PackerM.: Oral Vasodilator Therapy for Chronic Heart Failure: A Plea for Caution, Am. J. Cardiol.42: 686–689, 1978.
4.
PackerM.: Hemodynamic and Clinical Tachyphylaxis to Prazosin Mediated Afterload Reduction in Severe Chronic Congestive Heart Failure, Circulation59: 531–539, 1979.
5.
PackerM.: Rapid Hemodynamic Tachyphylaxis to Prazosin-mediated Afterload Reduction in Refractory Heart Failure (Abstract), Clin. Res.26: 257A, 1978.
6.
Graham: Prazosin: The First-Dose Phenomenon, Br. Med. J.2: 1293–1295, 1976.
7.
ChatterjeeK.: Long-Term Outpatient Vasodilator Therapy of Congestive Heart Failure, Am. J. Med.65: 134–145, 1978.
8.
ChatterjeeK.: Sustained Beneficial Hemodynamic Effects During Long-Term Hydralazine Therapy in Patients with Chronic Heart Failure, Circulation58 (supp. II): 11–28, 1978.
9.
FranciosaJ.: Hemodynamic Improvement after Oral Hydralazine in Left Ventricular Failure, Ann. Intern. Med.86: 388, 1977.
